Skip Navigation LinksHomeProductsProduct Details
Product In-Details

Salofalk ® 500 tablets

MINAPHARM- Egypt(under license of Dr. Falk- Germany) was honored since the beginning of this millennium to introduce to the Egyptian Pharmaceutical Market the branded Mesalazine, Salofalk®; The Active Principle where it is required.

Ingredient: Mesalazine 500mg
Multinational Partner: Dr. Falk Pharma
Launch Date: January 1, 2000
Pack: Salofalk® is available in a box of two strips, each strip contains ten enteric-coated tablets.

Product General

Disease Area

Salofalk is indicated in (IBD) Inflammatory Bowel Diseases: 

(1) Crohn's Disease.

(2) Ulcerative Colitis.

Where the normal mucosal homeostasis is altered with reduced ability of the GIT to distinguish foreign from self-antigens, or to down-regulate the mucosal immune response. This makes the self-limited Immune Elimination process proceeds to the Amplification Phase then to the Damage Phase.

Insert leaflet

INDICATIONS:

Prophylaxis and treatment of IBD recurrence (Ulcerative Colitis). Treatment of acute attacks of Crohn's disease.

DOSAGE:

1.5 gm to 4 gm daily according to severity 1 hour before eating.

Newsletter Sign-up

Stay connected, subscribe to our newsletter
for news and updates.

   

Office Address

El-Bardissi St., 2T Takseem Asmaa Fahmy St., Heliopolis,
Cairo - Egypt.
Phone:(+202) 2414-3170/1/2/3/4/5
Fax:(+202) 2414-3179